Skip to main content
Clinical Trials/NCT00705289
NCT00705289
Completed
Not Applicable

Epidemiology, Correlation and Predictive Value of Disease Activity and Biomarkers in RA Patients Initiated on Infliximab in Clinical Practice

Merck Sharp & Dohme LLC0 sites728 target enrollmentDecember 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rheumatoid Arthritis
Sponsor
Merck Sharp & Dohme LLC
Enrollment
728
Primary Endpoint
Baseline Raw Disease Activity Score for 28 Joint Swollen and Tender Joint Count (DAS28) by Age
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

This 14-week non-interventional study will observe patients with rheumatoid arthritis (RA) who are being treated with infliximab for the first time, in order to learn about their disease characteristics. Patients in this study will be treated for RA with infliximab and in a usual manner as decided by their physician.

Registry
clinicaltrials.gov
Start Date
December 2005
End Date
September 2008
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject has been diagnosed with RA
  • Physician has decided, with the subject's consent, to begin treatment with infliximab
  • Written informed consent form signed by both the subject and the physician.

Exclusion Criteria

  • Subjects who have previously been exposed to infliximab

Outcomes

Primary Outcomes

Baseline Raw Disease Activity Score for 28 Joint Swollen and Tender Joint Count (DAS28) by Age

Time Frame: At Baseline

Results are reported as the mean DAS28 raw score at Baseline. DAS28 is a unit scale from 2.0 (best value) to 10.0 (worst value). The relationship between Baseline Raw DAS28 and Baseline age (see Baseline Characteristics) is reported in the statistical analysis.

Baseline Raw DAS28 by Time Since Diagnosis

Time Frame: At Baseline

Results are reported as the mean DAS28 raw score at Baseline. DAS28 is a unit scale from 2.0 (best value) to 10.0 (worst value). The relationship between Baseline Raw DAS28 and time since diagnosis is reported in the statistical analysis.

Baseline Raw DAS28 by Gender

Time Frame: At Baseline

Results are reported as the mean DAS28 raw score at Baseline. DAS28 is a unit scale from 2.0 (best value) to 10.0 (worst value). The relationship between Baseline Raw DAS28 and Baseline gender (see Baseline Characteristics) is reported in the statistical analysis.

Baseline Raw DAS28 by Country of Residence

Time Frame: At Baseline

Results are reported as the mean DAS28 raw score at Baseline. DAS28 is a unit scale from 2.0 (best value) to 10.0 (worst value). The relationship between Baseline Raw DAS28 and Baseline Characteristic is reported in the statistical analysis.

Baseline Raw DAS28 by Previous Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Time Frame: At Baseline

Results are reported as the mean DAS28 raw score at Baseline. DAS28 is a unit scale from 2.0 (best value) to 10.0 (worst value). The relationship between DAS28 and baseline characteristic is reported in the statistical analysis.

Similar Trials